Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): A randomised, open-label, phase 3 trial

The Lancet Oncology

Volumn 15, Issue 7, 2014, Pages 689-699

  Krop, Ian E ^a   Kim, Sung Bae ^b   González Martín, Antonio ^c   LoRusso, Patricia M ^d   Ferrero, Jean Marc ^e   Smitt, Melanie ^f   Yu, Ron ^f   Leung, Abraham C F ^f   Wildiers, Hans ^g  

^a HARVARD MEDICAL SCHOOL   (United States)

^b University of Ulsan College of Medicine   (South Korea)

^c MD ANDERSON CANCER CENTER   (Spain)

^d WAYNE STATE UNIVERSITY   (United States)

^e CENTRE ANTOINE LACASSAGNE   (France)

^f GENENTECH INC   (United States)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DEATH; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAZARD RATIO; HER2 POSITIVE ADVANCED BREAST CANCER; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SYSTEMIC THERAPY; THROMBOCYTOPENIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MAYTANSINE; MIDDLE AGED; RECEPTOR, ERBB-2;

EID: 84901639476     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70178-0     Document Type: Article

References (31)

1. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013, 31:3997-4013.
2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
3. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23:4265-4274.
4. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
5. von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009, 27:1999-2006.
6. Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 2012, 30:2585-2592.
7. NCCN Breast Cancer Guidelines, version 3.2014 National Comprehensive Cancer Network, (accessed Jan 14, 2014). http://www.nccn.org/professionals/physician_gls/recently_updated.asp.
8. Mohd Sharial MS, Crown J, Hennessy BT Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann Oncol 2012, 23:3007-3016.
9. Gori S, Montemurro F, Spazzapan S, et al. Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Ann Oncol 2012, 23:1436-1441.
10. Di Lauro V, Torrisi E, Bidoli E, Quitadamo D, Cecco S, Veronesi A Trastuzumab and gemcitabine in pretreated HER2 overexpressing metastatic breast cancer patients: retrospective analysis of our series. J Oncol 2012, 2012:198412.
11. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008, 68:9280-9290.
12. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011, 128:347-356.
13. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012, 367:1783-1791. the EMILIA Study Group.
14. Burris HA, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011, 29:398-405.
15. Krop IE, LoRusso P, Miller KD, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 2012, 30:3234-3241.
16. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
17. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 US Department of Health and Human Services, (accessed Jan 14, 2014). http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf.
18. Ado-trastuzumab emtansine (KADCYLA) prescribing information 2013, Genentech, Genentech, Inc, South San Francisco, CA.
19. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28:1124-1130.
20. Welslau M, Diéras V, Sohn JH, et al. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer 2014, 120:642-651.
21. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
22. Wang L, Zhang Q, Zhang J, et al. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 2011, 11:248.
23. Lopus M, Oroudjev E, Wilson L, et al. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther 2010, 9:2689-2699.
24. Baselga J, Verma S, Ro J, et al. Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC). Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; Washington, DC; April 6-10, 2013. Abstract LB-63.
25. Thon JN, Devine MT, Jurak Begonja A, Tibbitts J, Italiano JE High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production. Blood 2012, 120:1975-1984.
26. Thon JN, Devine MT, Jurak Begonja A, Tibbitts J, Italiano JE Jr. Trastuzumab emtansine (T-DM1)-induced thrombocytopenia results from impaired platelet production in a HER2-independent manner. Presented at AACR-EORTC-NCI International Conference: Molecular Targets and Cancer Therapeutics; San Francisco, CA; November 12-16, 2011.
27. Fabi A, Di Benedetto A, Metro G, et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res 2011, 17:2055-2064.
28. Xiao C, Gong Y, Han EY, Gonzalez-Angulo AM, Sneige N Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment. Ann Oncol 2011, 22:1547-1553.
29. Dodd LE, Korn EL, Freidlin B, et al. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?. J Clin Oncol 2008, 26:3791-3796.
30. Amit O, Mannino F, Stone AM, et al. Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis. Eur J Cancer 2011, 47:1772-1778.
31. Zhang JJ, Chen H, He K, et al. Evaluation of blinded independent central review of tumor progression in oncology clinical trials: a meta-analysis. Drug Inf J 2013, 47:167-174.